Bicycle Therapeutics (NASDAQ:BCYC) Raised to Hold at Wall Street Zen

Bicycle Therapeutics (NASDAQ:BCYC) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

Other analysts have also recently issued research reports about the company. Morgan Stanley reissued a “sell” rating and set a $13.00 price objective on shares of Bicycle Therapeutics in a research report on Tuesday. Citizens Jmp lowered their price target on Bicycle Therapeutics from $12.00 to $8.00 and set a “market outperform” rating for the company in a research note on Wednesday. Needham & Company LLC lowered their price target on Bicycle Therapeutics from $24.00 to $15.00 and set a “buy” rating for the company in a research note on Wednesday. Royal Bank Of Canada dropped their price objective on Bicycle Therapeutics from $11.00 to $7.00 and set a “sector perform” rating on the stock in a report on Wednesday. Finally, Jefferies Financial Group raised shares of Bicycle Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Bicycle Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $14.50.

Bicycle Therapeutics Stock Performance

Shares of BCYC opened at $4.35 on Friday. The company has a market capitalization of $301.75 million, a PE ratio of -1.38 and a beta of 1.65. The company’s 50 day moving average price is $5.78 and its 200 day moving average price is $6.76. Bicycle Therapeutics has a 52 week low of $4.30 and a 52 week high of $9.69.

Bicycle Therapeutics (NASDAQ:BCYC) last released its earnings results on Tuesday, March 17th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.71. Bicycle Therapeutics had a negative net margin of 301.66% and a negative return on equity of 33.21%. The company had revenue of $47.96 million during the quarter, compared to the consensus estimate of $7.08 million. On average, equities analysts forecast that Bicycle Therapeutics will post -3.06 earnings per share for the current fiscal year.

Insider Transactions at Bicycle Therapeutics

In other news, CFO Alethia Young sold 4,334 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $6.49, for a total transaction of $28,127.66. Following the completion of the sale, the chief financial officer owned 87,081 shares in the company, valued at approximately $565,155.69. This represents a 4.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin Lee sold 10,989 shares of the stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $6.46, for a total value of $70,988.94. Following the transaction, the chief executive officer directly owned 618,996 shares in the company, valued at approximately $3,998,714.16. This represents a 1.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 38,029 shares of company stock valued at $251,966 in the last ninety days. Insiders own 22.90% of the company’s stock.

Hedge Funds Weigh In On Bicycle Therapeutics

A number of institutional investors have recently modified their holdings of BCYC. Assetmark Inc. lifted its stake in shares of Bicycle Therapeutics by 74.9% in the third quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock worth $28,000 after buying an additional 1,552 shares during the last quarter. Clearstead Advisors LLC grew its stake in Bicycle Therapeutics by 234.2% in the 4th quarter. Clearstead Advisors LLC now owns 4,655 shares of the company’s stock valued at $33,000 after buying an additional 3,262 shares during the last quarter. Pinnacle Wealth Management Advisory Group LLC acquired a new position in Bicycle Therapeutics in the 4th quarter valued at $71,000. Ausdal Financial Partners Inc. bought a new position in Bicycle Therapeutics in the 2nd quarter worth $70,000. Finally, Vontobel Holding Ltd. acquired a new position in Bicycle Therapeutics during the 4th quarter worth $71,000. Institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.